| Size | Price | Stock | Qty |
|---|---|---|---|
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| Other Sizes |
|
| Targets |
|
|
|---|---|---|
| ln Vitro |
In HepG2 cells, aflatoxilactone dose-dependently promotes apoptosis. According to studies, this apoptosis caused by alanolactone is linked to several factors, including increased Bax/Bcl-2 ratio, caspase-3 activation, ROS production, GSH depletion, and suppression of STAT3 activation [1]. The expression of STAT3 target genes, DNA binding, and translocation to the nucleus are all decreased by aminolactone. Though this impact is not mediated by inhibition of STAT3 upstream kinases, amyloidolactone dramatically reduces STAT3 activation and has minor effects on MAPK and NF-κB transcription [2]. In HCT-8 human colon cancer cells, alantolactone triggers activin/SMAD3 signaling. By preventing Cripto-1 and type IIA activin receptors from interacting in the activin signaling pathway, alantolactone has anti-tumor properties [4]. The growth of colon adenocarcinoma HCT-8 cells is inhibited by aflatolactone (5 μg/mL, 24 h) [4].
|
|
| ln Vivo |
When compared to control mice, the average tumor volume in mice treated with alanylactone was shown to be roughly 2.17 times smaller. Nonetheless, during the trial period, the administration of alanolactone had no effect on total body weight, suggesting no appreciable harm. Furthermore, compared to control mice, the average tumor weight of mice treated with alanylactone was considerably lower. More significantly, cyclin D1 and p-STAT3 expression in tumor tissues were significantly reduced after injection of alantolactone [2].
|
|
| Cell Assay |
Cell Viability Assay[4]
Cell Types: HCT-8 cells. Tested Concentrations: 5 μg/mL (~21.6 μM). Incubation Duration: 24 h. Experimental Results: Activated the activin signaling pathway in HCT-8 cells. |
|
| Animal Protocol |
Animal/Disease Models: Female athymic BALB/c nude mice at the age of 6 weeks[2].
Doses: 2.5 mg/kg. Route of Administration: IP injection every 2 days. Experimental Results: demonstrated anti-cancer activity. |
|
| References |
|
|
| Additional Infomation |
Alantolactone is a sesquiterpene lactone that is 3a,5,6,7,8,8a,9,9a-octahydronaphtho[2,3-b]furan-2-one bearing two methyl substituents at positions 5 and 8a as well as a methylidene substituent at position 3. It has a role as a plant metabolite, an apoptosis inducer and an antineoplastic agent. It is a sesquiterpene lactone, a naphthofuran and an olefinic compound.
Alantolactone has been reported in Inula grandis, Inula japonica, and other organisms with data available. |
| Molecular Formula |
C15H20O2
|
|---|---|
| Molecular Weight |
232.323
|
| Exact Mass |
232.146
|
| CAS # |
546-43-0
|
| PubChem CID |
72724
|
| Appearance |
White to off-white solid powder
|
| Density |
1.1±0.1 g/cm3
|
| Boiling Point |
275.0±0.0 °C at 760 mmHg
|
| Melting Point |
78-79ºC
|
| Flash Point |
111.5±18.2 °C
|
| Vapour Pressure |
0.0±0.5 mmHg at 25°C
|
| Index of Refraction |
1.534
|
| LogP |
3.69
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
0
|
| Heavy Atom Count |
17
|
| Complexity |
421
|
| Defined Atom Stereocenter Count |
4
|
| SMILES |
C[C@H]1CCC[C@]2(C1=C[C@H]3[C@@H](C2)OC(=O)C3=C)C
|
| InChi Key |
PXOYOCNNSUAQNS-AGNJHWRGSA-N
|
| InChi Code |
InChI=1S/C15H20O2/c1-9-5-4-6-15(3)8-13-11(7-12(9)15)10(2)14(16)17-13/h7,9,11,13H,2,4-6,8H2,1,3H3/t9-,11+,13+,15+/m0/s1
|
| Chemical Name |
(3aR,5S,8aR,9aR)-5,8a-dimethyl-3-methylidene-5,6,7,8,9,9a-hexahydro-3aH-benzo[f][1]benzofuran-2-one
|
| Synonyms |
AI3-31147Alantolactone AI331147 AI3 31147
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~430.44 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (10.76 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (10.76 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (10.76 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.3044 mL | 21.5220 mL | 43.0441 mL | |
| 5 mM | 0.8609 mL | 4.3044 mL | 8.6088 mL | |
| 10 mM | 0.4304 mL | 2.1522 mL | 4.3044 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
